{"id":"NCT00528840","sponsor":"Endo Pharmaceuticals","briefTitle":"Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","officialTitle":"A Phase 3, Open-Label Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2007-09-12","resultsPosted":"2010-10-22","lastUpdate":"2017-12-02"},"enrollment":201,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Dupuytren's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"collagenase clostridium histolyticum","otherNames":["XIAFLEX®","AA4500"]}],"arms":[{"label":"AA4500 0.58 mg","type":"EXPERIMENTAL"}],"summary":"This was a Phase 3, 9-month, open-label study conducted in the United States. Subjects with a diagnosis of advanced Dupuytren's disease in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint that resulted in a fixed flexion deformity of at least one finger, other than the thumb, that was at least 20° as measured by finger goniometry and was suitable for evaluation and injection were enrolled.\n\nThis study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.","primaryOutcome":{"measure":"Reduction in Contracture to 5° or Less","timeFrame":"Within 30 days after the last injection","effectByArm":[{"arm":"AA4500 0.58 mg","deltaMin":52.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125338lbl.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":201},"commonTop":["Oedema peripheral","Injection site pain","Injection site haemorrhage","Contusion","Injection site swelling"]}}